Study of efficacy and side effects of Pioglitazone in the treatment of psoriasis
- Conditions
- Psoriasis.Psoriasis vulgaris
- Registration Number
- IRCT138903013862N2
- Lead Sponsor
- Research Council of Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 26
new cases of plaque psoriasis which don’t received systematic treatment during last 3 months and for topical treatment last month, patients complete consent form and participate to study consciously. Exclusion criteria: patients who want to leave study deliberately, sensitive to pioglitazone or the same preparations, type one diabetes mellitus, pregnant or lactating women, below 18 years old, with severe hepatic problems (hepatitis, alcoholic or non alcoholic steatohepatitis, cirrhosis), severe cardiovascular disorders (NYHA CLASS III & IV), patients prevent pregnancy only by oral contraceptives, patients that have any of these following side effects during therapy: upper respiratory tract infections and sinusitis, edema and any indicative sign of heart failure, unwanted pregnancy, weight gain, anemia, leuckopenia, hematuria, jaundice and 3 times increment of hepatic enzymes (ALT), any symptom which make patients to leave the study. Patients who used any of these drugs (Oral contraceptives, Gatifloxacin ,Insulin ,sulfunamides ,sulfunylureas, Thioridazine , Gemfibrozil).
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Psoriasis severity. Timepoint: monthly untill the end of 12 weeks. Method of measurement: PASI standard method.
- Secondary Outcome Measures
Name Time Method Side effect. Timepoint: monthly untill end of 12 weeks. Method of measurement: Standard evaluation method for this disease.